A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2006
11/23/2006	WO2006122447A1 Medicament for treating drugs abuse comprising peroxidase and its use
11/23/2006	WO2006122353A1 Methods and compositions for the treatment of pain
11/23/2006	WO2006110884A3 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
11/23/2006	WO2006087306A3 Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors
11/23/2006	WO2006084870A3 Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
11/23/2006	WO2006084015A3 Raf inhibitor compounds and methods
11/23/2006	WO2006076317A3 Aminophenyl derivatives as selective androgen receptor modulators
11/23/2006	WO2006075011A3 Glycine reuptake inhibitors for treating drug and alcohol dependence
11/23/2006	WO2006071538A3 Substituted biaryl analogues
11/23/2006	WO2006061372A3 Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites
11/23/2006	WO2006047250A3 Use of apoptosis inhibiting compounds in degenerative neurological disorders
11/23/2006	WO2006044449A3 Cgrp receptor antagonists
11/23/2006	WO2006029154A3 Novel compounds
11/23/2006	US20060264638 Useful in the treatment of chronic and acute pain; 1-[4-dibenzocycloheptyl-4-piperidinyl]-1,3-dihydro-2H-1,3-benzamidazol-2-one;
11/23/2006	US20060264628 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
11/23/2006	US20060264496 Substituted indoline and indole derivatives
11/23/2006	US20060264493 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
11/23/2006	US20060264479 Nicotinamide Derivatives Useful as p38 Inhibitors
11/23/2006	US20060264474 novel sulphonamide, sulphamate and sulphamide derivatives, comprising a m-disubstituted benzene or pyridine ring and a substituted pyrazole moiety, which inhibit the processing of APP by gamma -secretase, and hence are useful in the treatment or prevention of Alzheimer's disease
11/23/2006	US20060264471 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derviatives and use thereof as medicines for treating schizophrenia
11/23/2006	US20060264470 e.g. 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-3-methyl-N-piperidin-1-ylthiophene-2-carboxamide; cannabinoid receptor antagonist; antiinflammatory agent; obesity, gastrointestinal disorders, inflammatory phenomena, immune system diseases, psychotic disorders, alcohol and nicotine dependence
11/23/2006	US20060264466 N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ; antipsychotic and anti-dyskinetic; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
11/23/2006	US20060264465 N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ; antipsychotic and anti-dyskinetic; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
11/23/2006	US20060264464 Amidino compounds as cysteine protease inhibitors
11/23/2006	US20060264456 Phosphorus-containing compounds & uses thereof
11/23/2006	US20060264452 Analgesics; immunomodulators and for treatment of drug dependence; for example, 5'-Bromo-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5 alpha -epoxypyrido[2',3':6,7]morphinan
11/23/2006	US20060264441 N-[(1-azabicyclo[2.2.2]oct-2-yl)arylmethyl]-benzamide derivatives; psychological, behavioral, eating, sexual, sleep, nervous system, and/or neurodegenerative disorders; drug abuse, alcoholism, schizophrenia, psychoses, Parkinson*s disease, epilepsy; analgesics, antidepressants, anxiolytic agents
11/23/2006	US20060264437 Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists
11/23/2006	US20060264436 Method of Treating a Psychotic Disorder
11/23/2006	US20060264432 Adenosine A1, A2a, and A2b receptor ligands; coupling the 2-mercapto-3,5-dicyano-4-aryl-6-aminopyridine to a substituted alkyl or alkenyl compound; antiischemic agents; cardiovascular disorders
11/23/2006	US20060264429 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
11/23/2006	US20060264419 Substituted pyrazoles
11/23/2006	US20060264418 6-(2,2,2-Trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist
11/23/2006	US20060264417 N-(3-tetrahydrobenzodiazepinonyl)succamides: 2R,3S)N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide; inhibit production of A beta -peptide, preventing neurological amyloid deposits; Alzheimer's disease
11/23/2006	US20060264397 Compositions and methods for targeting cancer cells
11/23/2006	US20060264363 Inhibition of nerve cell death by inhibiting degradation of shc3, atf6 or crebl1 by htra2 and method of ameliorating neurodegenerative diseases
11/23/2006	US20060263852 Asp2
11/23/2006	US20060263437 Pharmaceutical microspheres containing valproic acid for oral administration
11/23/2006	US20060263431 Opioid Sustained Release Formulation
11/23/2006	US20060263407 Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants
11/23/2006	US20060263388 Injectable or oral administration of a drug with an active ingredient of an extract from inflamed cutaneous tissue of rabbits inoculated with vaccinia virus; side effect reduction
11/23/2006	US20060263359 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
11/23/2006	DE102005023207A1 New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease
11/23/2006	DE102005022845A1 Thiobernsteinsäurederivate und deren Verwendung Thiobernsteinsäurederivate and their use
11/23/2006	CA2609814A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006	CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006	CA2609059A1 Methods and compositions for the treatment of pain
11/23/2006	CA2609002A1 Use of 2,5-disubstituted thiazol-4-one derivatives in the production of drugs for the treatment of disorders or diseases which are mediated at least partly by vanilloid receptors 1(vr1/trpv1 receptors)
11/23/2006	CA2608767A1 Nucleic acids and polypeptides that are useful in controlling neuronal regeneration
11/23/2006	CA2608690A1 Stable tablet containing droxidopa
11/23/2006	CA2608324A1 Pyrolle derivatives as positive allosteric modulators of metabotropic glutamate receptors
11/23/2006	CA2608240A1 Multicyclic compounds and methods of their use
11/23/2006	CA2608014A1 Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
11/23/2006	CA2608012A1 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
11/23/2006	CA2607472A1 Antipyretic agents against vr1-antagonist-induced increases in body temperature
11/23/2006	CA2604562A1 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
11/23/2006	CA2601800A1 Oral drug delivery system
11/22/2006	EP1724339A1 Gene regulation therapy involving ferritin
11/22/2006	EP1724279A2 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia.
11/22/2006	EP1724278A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
11/22/2006	EP1724270A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/22/2006	EP1724267A1 Pyrimidine derivative
11/22/2006	EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient
11/22/2006	EP1724257A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
11/22/2006	EP1723969A1 Granulocyte-macrophage colony-stimulating factor (GM-CSF) as remedy for nerve damages
11/22/2006	EP1723968A1 Erythrocyte function modifying substance
11/22/2006	EP1723959A1 Composition comprising platelet-rich plasma
11/22/2006	EP1723957A2 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
11/22/2006	EP1723953A1 Nutritional supplements
11/22/2006	EP1723950A2 Method of treating dopaminergic gaba-nergic disorders
11/22/2006	EP1723144A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
11/22/2006	EP1723134A2 Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
11/22/2006	EP1723102A2 N-substituted benzene sulfonamides
11/22/2006	EP1599205B1 Pten inhibitor or maxi-k channels opener
11/22/2006	EP1554243B1 Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases
11/22/2006	EP1511770B1 Glycoprotein vi-fc fusion protein for the treatment of vascular diseases
11/22/2006	EP1497291B1 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
11/22/2006	EP1483265B1 Purine derivatives as kinase inhibitors
11/22/2006	EP1467982B1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
11/22/2006	EP1461034B1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines
11/22/2006	EP1458721B1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/22/2006	EP1430308B1 Screening method for different indications using bnpi and/or dnpi
11/22/2006	EP1392287B1 Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
11/22/2006	EP1351933B1 Il-8 receptor antagonists
11/22/2006	EP1342472B1 Analgesic and anti-inflammatory patches for external use containing 4-biphenylylacetic acid
11/22/2006	EP1317450B1 Pyrazole compounds useful as protein kinase inhibitors
11/22/2006	EP1311272B1 Novel methods using cholinesterase inhibitors
11/22/2006	EP1268435B1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity
11/22/2006	EP1268412B1 Sulphonamido-substituted bridged bicycloalkyl derivatives
11/22/2006	EP1220682B1 Stabilized liquid polypeptide-containing pharmaceutical compositions
11/22/2006	EP1173465B1 Novel human voltage-gated potassium channel
11/22/2006	EP1163522B1 Method for detecting msrv-1 induced superantigen activity in a biological sample
11/22/2006	EP1051395B1 N-hydroxyformamide derivatives
11/22/2006	EP1051176B1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/22/2006	EP0942925B1 Inhibitors of interleukin-1 beta converting enzyme
11/22/2006	EP0939821B1 G-beta-gamma regulated phosphatidylinositol-3' kinase
11/22/2006	EP0890105B1 Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
11/22/2006	EP0825996B1 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use
11/22/2006	CN1867560A 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
11/22/2006	CN1867554A Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors

1 ... 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 ... 1833